One dose of gene-editing drug cut bad cholesterol 62% for months in small trial
SMRTR summary
A single infusion of an experimental gene-editing drug called VERVE-102 cut bad cholesterol by 62% in early trial participants, with effects lasting up to 18 months. The drug permanently disables a gene controlling cholesterol levels in the liver. Eli Lilly, which acquired the drug for $1.3 billion, hopes it could replace lifetime cholesterol medications.
SMRTR provides this summary for quick context. The original article belongs to Ars Technica.
Read the original article